Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29228053 | 0.82 | ALOX5 (0.34) | CDK2GRM5 | |
| SCHEMBL22924886 | 0.82 | CSF1R (0.33) | CDK2CCR4GRM5PDE4APDE4B | |
| SCHEMBL22924868 | 0.80 | CYP2C19 (0.35) | CDK2GRM5PDE4APDE4BPDE4C | |
| SCHEMBL30416548 | 0.80 | CYP2C19 (0.35) | CDK2GRM5PDE4APDE4BPDE4C | |
| SCHEMBL21384637 | 0.78 | GRM5 (0.35) | CDK2GRM5CTSACYP2C19 | |
| SCHEMBL30980583 | 0.78 | CSF1R (0.35) | CDK2GRM5PDE4APDE4BPDE4C | |
| SCHEMBL24768930 | 0.77 | CYP17A1 (0.35) | — | |
| SCHEMBL29963510 | 0.77 | CYP17A1 (0.35) | — | |
| SCHEMBL22924885 | 0.77 | CYP2C19 (0.33) | CDK2GRM5CTSACYP2C19 | |
| SCHEMBL30416534 | 0.77 | CYP2C19 (0.33) | CDK2GRM5CTSACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402881-A1 | SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402881-A1 | SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS | PTGER1, PTGIS, PTGIR | CDK2 2985/4885CCR4 3711/4885GRM5 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.